Back To Search Instructions
Protocols
101 protocols meet the specified criteria
Protocol No.TitleStatus
2012-9205Magnetic resonance imaging of the healthy knee cartilage with T2 and T1rho mappingOpen (affiliates only)
2013-9590Magnetic resonance imaging of knee cartilage degeneration with T2 and T1rho mappingOpen (affiliates only)
ALLIANCE-A221101A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma Open
CALGB-70807The Mens Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active SurveillanceOpen
CALGB-90203(CIRB) A Randomized Phase III Study Of Neo-Adjuvant Docetaxel And Androgen Deprivation Prior To Radical Prostatectomy Versus Immediate Radical Prostatectomy In Patients With High-Risk, Clinically Localized Prostate CancerOpen
CALGB-90601(CIRB) A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell CarcinomaOpen
CALGB-C80802(CIRB) Phase III Randomized Study of Sorafenib plus Doxorubicin Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Open
COG-AEWS1031(CIRB) Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing SarcomaOpen
ECOG-E2108(CIRB) A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast CancerOpen
ECOG-E2211A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine TumorsOpen
ECOG-E2607A Phase II Trial of Dasatinib in KIT-Positive Patientswith Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal MelanomasOpen
ECOG-E3A06(CIRB) Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple MyelomaOpen
ECOG-E5202A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patietns with Stage II Colon Cancer at High Risk for REcurrence to Determine Prospectivitely the Prognostic Value of Molecular MarkersOpen (affiliates only)
GOG-0212A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles Of Single Agent Paclitaxel Or CT-2103 (IND# 70177), Versus No Treatment Until Documented Relapse In Women With Advanced Ovarian, Primary Peritoneal Or Fallopian Tube Cancer Who Achieve A Complete Clinical Response To Primary Platinum/Taxane ChemotherapyOpen (affiliates only)
GOG-0237Comparative Analysis Of CA-IX, p16, Proliferative Markers And Human Papilloma Virus (HPV) In The Diagnosis Of Significant Cervical Lesions In Patients With A Cytologic Diagnosis Of Atypical Glandular Cells (AGC)Open
GOG-0274(CIRB) A Phase III Trial of Adjuvant Chemotherapy as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial (ANZGOG 0902/GOG-0274/RTOG 1174) (CIRB Approved)Open
GOG-9928A Phase I Study Of Intraperitoneal EGEN-001 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) (IND #12,484) Administered In Combination With Pegylated Liposomal-Doxorubicin (PLD, Doxil (NSC#712227 or Lipodox (NSC#673089) In Patients With Recurrent Or Persistent Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal CancerOpen
GOG-9929A Phase I Trial of Sequential Ipilimumab after Chemoradiation for the Primary Treatment of Patients with Locally Advanced Cervical Cancer Stages IB2/IIA with Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA with Positive Lymph NodesOpen
NSABP-B-43(CIRB) A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy. (Appendix T)Open
NSABP-B-50-IA Randomized, Multicenter, Open-Label Phase III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine Versus Trastuzumab As Adjuvant Therapy For Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically In The Breast Or Axillary Lymph Nodes Following Preoperative TherapyOpen
RTOG-0848(CIRB) Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma Open
RTOG-1010(CIRB) A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment Of HER2-Overexpressing Esophageal Adenocarcinoma Open
RTOG-1122Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 In Patients With Recurrent Glioblastoma Or GliosarcomaOpen
SWOG-C80702(CIRB) A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon CancerOpen
SWOG-N1048(CIRB) A Phase II/III Trial of Neoadjuvant FOLFOX with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision Open
SWOG-S0820A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III Open
SWOG-S0905A Phase I/Randomized Phase II Study of Cediranib (NSC # 732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma Open
SWOG-S1007(CIRB) Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast CancerOpen
SWOG-S1201A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) CancerOpen
SWOG-S1203(CIRB) A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)Open
SWOG-S1211A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)Open
SWOG-S1216(CIRB) A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer Open
SWOG-S1310Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary CancerOpen
UCI-01-61A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma (Appendix T)Open
UCI-03-03Immunologic Factors Affecting Outcomes in Patients with Liver CancerOpen
UCI-03-36Genetic Epidemiology of Pancreas Cancer Families: A Cancer Genetics Network Pilot StudyOpen
UCI-05-40Stress, Immunity, and Cervical Cancer: Biobehavioral Outcomes of a Randomized Trial [Promoting Women's Health]Open
UCI-06-13Evaluation of Predictive Signatures of Prostate CancerOpen
UCI-07-40Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Appendix T)Open
UCI-07-61A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting (Appendix T)Open
UCI-08-16A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma MultiformeOpen
UCI-08-51Near Infrared Optical Coherence Tomography of the Upper Aero-digestive TractOpen
UCI-09-17Biology of Human Melanocytes and KeratinocytesOpen
UCI-09-31A retrospective review of early invasive adenocarcinoma of the cervix and adenocarcinoma in situ (CHART REVIEW EXEMPT FROM NCI REPORTING; therefore, no further resources will be utilized to populate other data elements. See 2011 CCSG Outreach - Determination of Chart Review Protocols file)Open (affiliates only)
UCI-09-53A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects with Unresectable Stage III and Stage IV Melanoma (Appendix T)Open
UCI-10-11A Phase II Study to Evaluate the Effects of Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer PatientsOpen
UCI-10-13Pilot study comparing the Pharmacokinetics of Sorafenib in the Asian-American population vs. Non-Asian Population in the Treatment of Hepatocellular CarcinomaOpen
UCI-10-24ATHENA Breast Health NetworkOpen
UCI-10-37Diagnosis of Pancreatic Cysts: Endoscopic Ultrasound with fine needle aspiration (EUS/FNA), Direct visualization, and confocal laser-induced endomicroscopy--A Pilot StudyOpen
UCI-10-39Predicting pathological response within the first week of neoadjuvant chemotherapy using functional parameters measured with Diffuse Optical Spectroscopic Imaging (DOSI).Open
UCI-10-40Monitoring and Predicting Breast Cancer Neoadjuvant Chemotherapy Response Using Diffuse Optical Spectroscopic Imaging (DOSI) Open
UCI-10-44Role of Metabolic Enzymes in Skin Cancer: Potential for Informative Biomarkers and Therapeutic TargetsOpen
UCI-10-45Monitoring Chemotherapy Response of Soft Tissue Sarcomas and Osteosarcomas using Diffuse Optical Spectroscopic Imaging (DOSI).Open
UCI-10-50The Effects of Anti-Angiogenesis Agents on the Neuro-Cognitive Function of Patients Diagnosed with Recurrent, Treatment-Resistant GliomaOpen
UCI-10-52Therapeutic Potential of TOR Pathway Inhibitors in Pediatric ALLOpen
UCI-10-55Phase 2 Study of the Anti-Angiogenesis Agent Axitinib (AG-013736) in Patients with Stage III Malignant MelanomaOpen
UCI-10-56Quantification of breast density using dual energy mammography Open
UCI-11-02The Prostate Cancer Tumor Microenvironment Exhibits Differentially Expressed Genes Useful for DiagnosisOpen
UCI-11-05Testing the efficacy of kinase inhibitors in acute leukemia cells ex vivoOpen
UCI-11-16[DATABASE REVIEW] Data Linkage Study of Ship Yard Workers to Monitor Health OutcomesOpen
UCI-11-19Evaluation of Peritumoral Renal Adipose Tissue to Renal Cancer AggressivenessOpen
UCI-11-20OvaGene study of ovarian cancer biomarkersOpen
UCI-11-22A Pilot Study of Irinotecan in Patients with Breast Cancer and CNS MetastasesOpen
UCI-11-30Skin Imaging with Technologies in DevelopmentOpen
UCI-11-41A Phase II study of the BRAF inhibitor dabrafenib as a single agent and in combination with the MEK inhibitor trametinib in subjects with BRAF V600E mutation positive metastatic (stage IV) non-small cell lung cancer Open
UCI-11-46An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive GlioblastomaOpen
UCI-11-61A randomised, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of afatinib (BIBW 2992) as adjuvant therapy after chemo-radiotherapy in primary unresected patients with stage III, IVa, or IVb loco-regionally advanced head and neck squamous cell carcinomaOpen
UCI-11-65RObotic versus LAparoscopic Resection for Rectal cancer An international, multicentre, prospective, randomised, controlled, unblinded, parallel-group trial of robotic-assisted versus laparoscopic surgery for the curative treatment of rectal cancerOpen
UCI-12-01A Phase II Study of Rindopepimut/GM-CSF/GM-CSF in Patients with Relapsed EGFRvIII-Positive GlioblastomaOpen
UCI-12-04Pilot Project: Molecular Profiles of Refractory and Recurrent Childhood, Adolescent, and Young Adult CancersOpen
UCI-12-07Impact of the PARO Therapeutic Robot on Quality of Life in Gynecologic Cancer patients Receiving Chemotherapy at an Outpatient Infusion Center: A Prospective Pilot StudyOpen
UCI-12-08A Single-Arm Open-Label International Multi-Center Study Of The Efficacy And Safety Of Sunitinib Malate (SU011248, Sutent) In Patients With Progressive Advanced Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine TumorsOpen
UCI-12-09A phase 1, open-label, multiple ascending- dose study of ds-2248, an orally bioavailable heat shock protein 90 inhibitor, in subjects with advanced solid tumorsOpen
UCI-12-10Development of a Quantitative Tissue Optical Index of Breast Density for Prediction of Hormone Therapy Response Open
UCI-12-18(BIOREPOSITORY PROTOCOL) Comprehensive, Coordinated Clinical, Imaging and Histological Database for the Study of Neurological Outcomes of Cancer and Cancer TreatmentsOpen
UCI-12-32An Open-label, Randomized Phase 3 Study of Inotuzumab Ozogamicin Compared to a Defined Investigator's Choice in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)Open
UCI-12-33AirXpanders Patient Activated Controlled Tissue Expander System for Breast ReconstructionOpen
UCI-12-34A comparative Study of the Physiological Response, between AirSeal, an Integrated Insufflation and Access System, and Conventional Insufflation and TrocarsOpen
UCI-12-38A Prospective Observational Study Of Treatment Patterns And Effectiveness And Safety Outcomes In Advanced Basal Cell Carcinoma And Basal Cell Carcinoma Nevus Syndrome Patients - "RegiSONIC"Open
UCI-12-40Atlas Colorectal Health NetworkOpen
UCI-12-42A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving PazopanibOpen
UCI-13-02Assessing Fitness and Physical Activity in Acute Lymphoblastic Leukemia (ALL) Patients in RemissionOpen
UCI-13-06A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with Met Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic TherapyOpen
UCI-13-13Pilot study on in-vivo non-invasive skin imaging using multiphoton microscopyOpen
UCI-13-14A Randomized, Double-blinded, Placebo-controlled Phase 2 study of (ERC1671 + GM-CSF + Cyclophosphamide) + Bevacizumab vs. (Placebo Injection + Placebo pill) + Bevacizumab in the treatment of recurrent/progressive glioblastoma multiforme and gliosarcoma patients (WHO grade IV malignant gliomas) Open
UCI-13-22A randomized, double blind, placebo-controlled, multicenter phase III study of regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenibOpen
UCI-13-26A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination with TH-302 Compared with Gemcitabine in Combination with Placebo in Previously Untreated Subjects with Metastatic or Locally Advanced Unresectable Pancreatic AdenocarcinomaOpen
UCI-13-27Ovarian Cancer Patient-Centered Decision AidOpen
UCI-13-34Prospective international observational cohort non-comparative study describing the safety and effectiveness of ZALTRAP® administered in combination with FOLFIRI for the treatment of patients with metastatic colorectal cancer in current clinical practice: A Post-Authorisation Safety Study (PASS)Open
UCI-13-35A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects With Advanced Solid TumorsOpen
UCI-13-36A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant melanomaOpen
UCI-13-40Randomized controlled study comparing AEZS-108 with doxorubicin as second line therapy for locally advanced, recurrent or metastatic endometrial cancerOpen
UCI-13-41 The MILO Study (MEK Inhibitor in Low-grade Serous Ovarian Cancer): A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician's Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary PeritoneumOpen
UCI-13-42A Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian CancerOpen
UCI-13-53Protocol GO28609: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Adminstered Intravenously to Patients with Platinum-Resistant Ovarian CancerOpen
UCI-13-54A Phase I Dose-Escalation and Pharmacokinetic Study of Hyperthermic Intraoperative Intraperitoneal Chemotherapy (HIPEC) Carboplatin at the Time of Cytoreductive Surgery for the Initial Treatment of Advanced Ovarian, Fallopian Tube, and Peritoneal CarcinomasOpen
UCI-13-55A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)Open
UCI-14-03Role of inflammation in the pathogenesis of myeloproliferative neoplasm Open
UCI-95-29Measurement of Breast Tissue Optical PropertiesOpen
UCI-98-36Breast and Other Cancers in the California Teacher's CohortOpen
UCI-98-41Outcomes and Assessment of Prostate Cancer at UCIMCOpen